Studies on the Salvador I strain of Plasmodium vivax in non-human primates and anopheline mosquitoes

Am J Trop Med Hyg. 2009 Feb;80(2):228-35.

Abstract

A review is presented on studies conducted in New World monkeys and chimpanzees with the Salvador I strain of Plasmodium vivax. This isolate has been adapted to Aotus and Saimiri (squirrel) monkeys and developed as a model for the testing of antimalarial vaccines. After the injection of 10,000 sporozoites, the median prepatent period in S. boliviensis monkeys was 21.5 days. In 103 sporozoite-induced infections in splenectomized monkeys, the median maximum parasite count ranged from 2,139 to 202,368/microL, with a median maximum parasite count of 48,174/microL. Median maximum parasite counts in Aotus lemurinus griseimembra, A. nancymaae, A. azarae boliviensis, and A. vociferans monkeys were 19,902, 18,390, 21,420, and 18,210/microL, respectively and ranged from 124 to 156,000/microL. Mosquito infections were readily obtained in different species of Anopheles mosquitoes. The S. boliviensis monkey and Salvador I strain seems suitable for the testing of sporozoite and liver stage vaccines but not for blood-stage vaccines against P. vivax unless adapted further in spleen-intact Saimiri boliviensis monkeys.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Anopheles / parasitology*
  • Aotidae / parasitology*
  • Disease Models, Animal*
  • Humans
  • Liver / parasitology
  • Malaria Vaccines / therapeutic use
  • Malaria, Vivax / parasitology*
  • Malaria, Vivax / prevention & control
  • Plasmodium vivax / growth & development
  • Plasmodium vivax / pathogenicity*
  • Saimiri / parasitology*
  • Sporozoites / growth & development

Substances

  • Malaria Vaccines